This proposal responds to NIH RFA-AI-05-002. It describes the University of Washington Clinical HIV Integrated Research Program (UW CHIRP). The purpose of the UW CHIRP is to perform exemplary, cost effective HIV prevention and therapeutic research in adults, adolescents, and children. The UW CHIRP has been formed by integration of four existing, NIH-funded, network-affiliated HIV clinical research sites (CRSs). These CRSs are the UW HIV Prevention Trials Unit (HPTU) CRS, UW AIDS Clinical Trials Unit (ACTU) CRS, UW Primary Infection Clinic (PIC) CRS, and the UW International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) CRS. An administrative unit called the UW Clinical Trials Unit (CTU) will oversee the CRSs. The four CRSs will collaborate with the HIV Prevention Trials Network (HPTN), AIDS Clinical Trials Group (ACTG), ACTG, and the IMPAACT Group, respectively. UW CHIRP has five specific aims: 1) Organize, integrate, and coordinate the infrastructure, personnel, and facilities of UW and our CRSs to maximize efficiency and cost-effectiveness in conducting Network clinical trials;2) Ensure that all elements of the UW CHIRP meet necessary regulatory requirements, and perform to the standards of each affiliated Network;3) Foster new investigators and clinical research staff, especially women and minorities, and provide our clinical trials expertise to our Mentoring Partners;4) Contribute scientific expertise to the HPTN, ACTG, and IMPAACT Networks to develop and implement relevant scientific agendas, and to design protocols to support these Networks'scientific agendas and research plans;and 5) Organize, integrate, and coordinate our outreach efforts and connections to the community, including continuing our Prevention and Treatment Community Advisory Boards (CABs), to maximize access and enrollment of a broad diversity of subjects into Network protocols, including women, racial/ethnic minorities, and youth. The proposal describes the organization and management plan for each part of UW CHIRP;the scientific expertise, scientific contributions, and mentoring experience of its highly experienced investigators;and the plans for community interactions that will focus on reaching women, minorities and youth. It describes three proposed international Mentoring Partnerships that are extensions of ongoing collaborations. The UW CHIRP brings together a highly productive, experienced team of domestic investigators, each of whom has made a significant contribution to HIV prevention and/or therapeutic research. With the new structure, UW CHIRP will increase collaborations and efficiencies, and will continue to make major contributions to HIV prevention and therapeutic research in order to impact the worldwide HIV/AIDS epidemic. ADMINISTRATIVE COMPONENT:

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI069434-04
Application #
7743014
Study Section
Special Emphasis Panel (ZAI1-MPM-A (M2))
Program Officer
Pouliot, Eileen M
Project Start
2006-12-01
Project End
2013-11-30
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
4
Fiscal Year
2010
Total Cost
$1,160,810
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Hulgan, Todd; Ramsey, Benjamin S; Koethe, John R et al. (2018) Relationships between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons with HIV after 96 weeks of Antiretroviral Therapy. J Acquir Immune Defic Syndr :
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786
Elion, Richard A; Althoff, Keri N; Zhang, Jinbing et al. (2018) Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. J Acquir Immune Defic Syndr 78:62-72
Dubrow, Robert; Qin, Li; Lin, Haiqun et al. (2017) Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. J Acquir Immune Defic Syndr 75:382-390

Showing the most recent 10 out of 143 publications